InMode (INMD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.35
- Estimate
- $0.33
- Surprise
- +5.4%
- Score today
- 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
InMode (INMD) beat the $0.33 estimate with adjusted EPS of $0.35 — a clear 5.4% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates INMD Sell at 5.6/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +5.4% surprise compares with a +3.7% four-quarter average. Next scheduled report: 2027-02-09.
What supports the rating
- Strong earnings beat streak (3/4)
- Attractive valuation
What argues against it
- Analyst target reached - limited upside remaining
- Weak growth
- Below 200-day MA
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.15
- Stop
- $12.65
At 11.2× trailing and 9.8× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
INMD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $763.6M
- P/E (fwd)
- 9.8
- P/E (ttm)
- 11.2
- 52-week range
- $12.72–$16.67
- Off 52-week high
- 21.1%
- RSI (14)
- 45
- Volume vs avg
- 0.86×
- Score today
- 5.6/10